Abstract
The purpose of this study was to determine whether lysostaphin would enhance its anti-staphylococcal efficacy in combination with lysozyme. Minimum inhibitory concentrations (MICs) of lysostaphin and lysozyme were separately determined for 41 strains belonging to 10 different species of human staphylococci. Lysozyme was virtually inactive and showed MICs of 15 mg/ml. On the contrary, all strains were susceptible to lysostaphin and showed MICs ranging from 2.5 to 60 micrograms/ml for the different Staphylococcus species. When the MIC of lysostaphin was determined in media containing submultiples of the MIC of lysozyme, the values obtained were much lower. The reduction of the lysostaphin MIC ranged from 16- to 200-fold in the different species tested. In Staphylococcus aureus, in particular, the combination of lysostaphin with 1.5 mg of lysozyme per ml reduced the MIC of lysostaphin by 25-fold. The activities of two combinations of the two enzymes were evaluated: one combination was expected to be active on S. aureus only, and the other combination was expected to inhibit all Staphylococcus strains. The first combination (0.5 micrograms of lysostaphin plus 0.5 mg of lysozyme per ml) was inhibitory to all of the 84 S. aureus strains tested, whereas 137 of 151 strains of other Staphylococcus species were unaffected. On the contrary, all of the 235 Staphylococcus strains tested were inhibited by the second combination (4 micrograms of lysostaphin plus 5 mg of lysozyme per ml). The possible mechanisms of lysostaphin potentiation by lysozyme are considered, and the potential use of a lysostaphin-lysozyme combination for topical therapy of staphylococcal infections resistant to other antibiotics is discussed.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BROWDER H. P., ZYGMUNT W. A., YOUNG J. R., TAVORMINA P. A. LYSOSTAPHIN: ENZYMATIC MODE OF ACTION. Biochem Biophys Res Commun. 1965 Apr 23;19:383–389. doi: 10.1016/0006-291x(65)90473-0. [DOI] [PubMed] [Google Scholar]
- Chipman D. M., Sharon N. Mechanism of lysozyme action. Science. 1969 Aug 1;165(3892):454–465. doi: 10.1126/science.165.3892.454. [DOI] [PubMed] [Google Scholar]
- Ghuysen J. M. Use of bacteriolytic enzymes in determination of wall structure and their role in cell metabolism. Bacteriol Rev. 1968 Dec;32(4 Pt 2):425–464. [PMC free article] [PubMed] [Google Scholar]
- Heddaeus H., Heczko P. B., Pulverer G. Evaluation of the lysostaphin-susceptibility test for the classification of staphylococci. J Med Microbiol. 1979 Feb;12(1):9–15. doi: 10.1099/00222615-12-1-9. [DOI] [PubMed] [Google Scholar]
- Iversen O. J., Grov A. Studies on lysostaphin. Separation and characterization of three enzymes. Eur J Biochem. 1973 Oct 5;38(2):293–300. doi: 10.1111/j.1432-1033.1973.tb03061.x. [DOI] [PubMed] [Google Scholar]
- Klesius P. H., Schuhardt V. T. Use of lysostaphin in the isolation of highly polymerized deoxyribonucleic acid and in the taxonomy of aerobic Micrococcaceae. J Bacteriol. 1968 Mar;95(3):739–743. doi: 10.1128/jb.95.3.739-743.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kloos W. E., Schleifer K. H. Simplified scheme for routine identification of human Staphylococcus species. J Clin Microbiol. 1975 Jan;1(1):82–88. doi: 10.1128/jcm.1.1.82-88.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Martin R. R., White A. The reacquisition of staphylococci by treated carriers: a demonstration of bacterial interference. J Lab Clin Med. 1968 May;71(5):791–797. [PubMed] [Google Scholar]
- SCHINDLER C. A., SCHUHARDT V. T. LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS. Proc Natl Acad Sci U S A. 1964 Mar;51:414–421. doi: 10.1073/pnas.51.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Varaldo P. E., Grazi G., Soro O., Cisani G., Satta G. Simplified lyogroup system, a new method for routine identification of staphylococci: description and comparison with three other methods. J Clin Microbiol. 1980 Jul;12(1):63–68. doi: 10.1128/jcm.12.1.63-68.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wadstrom T., Vesterberg O. Studies on endo-beta-acetylglucosaminidase, staphylolytic peptidase, and N-acetylmuramyl-L-alanine amidase in lysostaphin and from Staphylococcus aureus. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;79(2):248–264. doi: 10.1111/j.1699-0463.1971.tb02152.x. [DOI] [PubMed] [Google Scholar]
- Zygmunt W. A., Tavormina P. A. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog Drug Res. 1972;16:309–333. doi: 10.1007/978-3-0348-7081-8_7. [DOI] [PubMed] [Google Scholar]